ORIC Pharmaceuticals Shares Drop After Rinzimetostat Trial Data Release
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Apr 01 2026
0mins
Should l Buy ORIC?
Source: seekingalpha
- Clinical Trial Results: ORIC Pharmaceuticals reported data from its Phase 1b trial of rinzimetostat (ORIC-944) in combination with Bayer's Nubeqa, showing at the recommended dose of 400 mg, patients had radiographic progression-free survival (rPFS) rates of 93%, 84%, and 84% at 3, 4, and 5 months, respectively, indicating a favorable safety profile for long-term use.
- Market Reaction: Despite the positive safety differentiation shown in the trial, ORIC's stock fell approximately 22% in after-hours trading, with analysts like JPMorgan's Anupam Rama suggesting that the market's reaction is an overreaction and does not reflect the potential value of rinzimetostat.
- Future Plans: ORIC intends to initiate a global Phase 3 trial in H1 2026 to evaluate the efficacy of rinzimetostat in combination with darolutamide against the physician's choice of other AR inhibitors or chemotherapy, aiming to further validate its therapeutic benefits.
- Competitive Advantage: The findings align with other PRC2 inhibitors in late-stage development and outperform standard treatments like Pfizer's Xtandi, highlighting ORIC's potential competitive edge in the prostate cancer treatment landscape.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy ORIC?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on ORIC
Wall Street analysts forecast ORIC stock price to rise
12 Analyst Rating
11 Buy
1 Hold
0 Sell
Strong Buy
Current: 10.750
Low
15.00
Averages
19.60
High
25.00
Current: 10.750
Low
15.00
Averages
19.60
High
25.00
About ORIC
ORIC Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on improving patients’ lives by Overcoming Resistance In Cancer. The Company is advancing a diverse pipeline of clinical and discovery stage therapies designed to counter resistance mechanisms in cancer by leveraging its expertise within three specific areas: hormone-dependent cancers, precision oncology and key tumor dependencies. The Company's clinical-stage product candidates include ORIC-944, an allosteric inhibitor of the polycomb repressive complex 2 (PRC2) via the EED subunit, being developed for prostate cancer, and ORIC-114, a brain penetrant inhibitor that selectively targets EGFR exon 20, HER2 exon 20 and EGFR atypical mutations, being developed across multiple genetically defined cancers. In addition, the Company is also developing multiple discovery stage precision medicines targeting other hallmark cancer resistance mechanisms. Its out-licensing candidates include ORIC-533 and ORIC-613.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
US Stocks Close Higher Amid Optimism Over Middle East Conflict Resolution
- Market Rally: The S&P 500 rose by 0.72%, the Dow Jones increased by 0.48%, and the Nasdaq 100 climbed by 1.18%, reflecting growing investor optimism regarding a potential resolution to the Middle East conflict, which has bolstered market confidence.
- Strong Economic Data: The US ADP employment change for March increased by 62,000, surpassing expectations of 40,000, while February retail sales rose by 0.6% month-over-month, indicating robust economic recovery that could influence Federal Reserve policy decisions.
- Interest Rate Expectations: Despite positive economic indicators, hawkish comments from St. Louis Fed President raised concerns about inflation and employment, leading to a mere 1% chance of a 25 basis point rate hike at the upcoming April FOMC meeting, reflecting cautious market sentiment.
- Divergent Stock Performances: Target Hospitality surged over 36% after securing a multi-year contract worth over $550 million, while Nike fell more than 15% due to revenue forecasts indicating a decline, highlighting the market's varied outlook on different companies' futures.
See More
Oric Pharmaceuticals Shares Plunge 28% Amid Safety Concerns
- Significant Stock Drop: Oric Pharmaceuticals' shares plummeted 28% on Wednesday, marking the largest single-day decline in over four years, primarily due to investor concerns regarding the tolerability of its prostate cancer drug at higher doses, although analysts suggest the sell-off may be exaggerated.
- Dose Adjustment: Oric announced a shift to a lower 400 mg dose of its investigational drug Rinzimetostat, which demonstrated a more manageable safety profile compared to the previously tested 600 mg dose, with plans to advance to a global Phase 3 trial in the first half of 2026.
- Analyst Ratings Maintained: Jones Research maintained a ‘Buy’ rating on Oric with a $25 price target, noting that the drug's efficacy appears comparable to Pfizer's competing drug Mevrometostat while potentially offering a better safety profile, indicating continued market confidence in the stock.
- Market Sentiment Shift: Despite the sharp decline in stock price, retail sentiment shifted from ‘neutral’ to ‘extremely bullish’, reflecting optimism about Oric's future potential, with some users expressing that the stock has
See More
US Stocks Rise on Optimism Over Middle East Conflict Resolution
- Market Rally: The S&P 500 Index rose by 0.97%, the Dow Jones Industrial Average by 0.86%, and the Nasdaq 100 by 1.45%, reflecting growing investor confidence amid optimism that the Middle East conflict may soon conclude, which could stabilize global markets.
- Strong Economic Data: The US ADP employment change for March increased by 62,000, surpassing expectations of 40,000, while February retail sales rose by 0.6% month-over-month, indicating robust economic recovery that may influence Federal Reserve policy decisions.
- Interest Rate Outlook: Despite a mere 1% chance of a 25 basis point rate hike at the upcoming FOMC meeting, hawkish comments from St. Louis Fed President raised concerns about inflation and employment risks, potentially affecting investor sentiment and market dynamics.
- Divergent Stock Performances: Target Hospitality surged by over 37% after securing a multi-year contract worth over $550 million, while Nike fell by more than 13% due to revenue forecasts indicating a decline, highlighting varied market reactions to company-specific news.
See More
US Stocks Rise on Optimism Over Middle East Conflict Resolution
- Market Optimism: The S&P 500 index rose by 0.52%, the Dow Jones Industrial Average by 0.43%, and the Nasdaq 100 by 0.68%, reflecting investor optimism regarding a potential resolution to the Middle East conflict, which has fueled a continuation of Tuesday's strong rally.
- Strong Economic Data: The US ADP employment change for March increased by 62,000, surpassing expectations of 40,000, while February retail sales rose by 0.6% month-over-month, exceeding the anticipated 0.5%, bolstering market confidence in economic recovery and potentially influencing future monetary policy.
- Interest Rate Expectations: Despite hawkish comments from the St. Louis Fed President putting pressure on stocks, the market is still pricing in only a 1% chance of a 25 basis point rate hike at the upcoming FOMC meeting on April 28-29, indicating a cautious optimism regarding economic growth.
- Notable Stock Performances: Target Hospitality's stock surged over 28% after securing a multi-year contract worth over $550 million, while nCino's forecast of $569 million to $573 million in subscription revenue for 2027 exceeded market expectations, highlighting strong demand in the tech and service sectors.
See More
Oric Pharmaceuticals Reports New Rinzimetostat Developments
- Clinical Trial Progress: Oric Pharmaceuticals has identified Rinzimetostat (ORIC-944) at a dose of 400 mg once daily as the recommended Phase 3 dose in its Phase Ib study, demonstrating a landmark 5-month radiographic progression-free survival (rPFS) of 84% in post-abiraterone metastatic castration-resistant prostate cancer patients, significantly outperforming standard therapies and indicating strong market competitiveness.
- Safety Profile Advantage: The drug exhibited a notably lower incidence of adverse events in the Phase Ib trial, with nearly all side effects classified as Grade 1 or 2, and far fewer treatment modifications compared to competitor regimens, highlighting its safety and tolerability in clinical applications.
- Future Trial Plans: Oric plans to initiate the Himalayas-1 Phase 3 registrational trial in the first half of 2026, aiming to enroll approximately 600 patients randomized to receive either Rinzimetostat in combination with Darolutamide or a physician's choice of AR inhibitor or chemotherapy, further validating its efficacy.
- Strong Financial Position: As of 2025, Oric reported $392.3 million in cash and cash equivalents, expected to fund its operational plans into the second quarter of 2028, demonstrating financial stability as it advances clinical trials and market expansion.
See More
ORIC Pharmaceuticals Shares Drop After Rinzimetostat Trial Data Release
- Clinical Trial Results: ORIC Pharmaceuticals reported data from its Phase 1b trial of rinzimetostat (ORIC-944) in combination with Bayer's Nubeqa, showing at the recommended dose of 400 mg, patients had radiographic progression-free survival (rPFS) rates of 93%, 84%, and 84% at 3, 4, and 5 months, respectively, indicating a favorable safety profile for long-term use.
- Market Reaction: Despite the positive safety differentiation shown in the trial, ORIC's stock fell approximately 22% in after-hours trading, with analysts like JPMorgan's Anupam Rama suggesting that the market's reaction is an overreaction and does not reflect the potential value of rinzimetostat.
- Future Plans: ORIC intends to initiate a global Phase 3 trial in H1 2026 to evaluate the efficacy of rinzimetostat in combination with darolutamide against the physician's choice of other AR inhibitors or chemotherapy, aiming to further validate its therapeutic benefits.
- Competitive Advantage: The findings align with other PRC2 inhibitors in late-stage development and outperform standard treatments like Pfizer's Xtandi, highlighting ORIC's potential competitive edge in the prostate cancer treatment landscape.
See More
US Stocks Close Higher Amid Optimism Over Middle East Conflict Resolution
- Market Rally: The S&P 500 rose by 0.72%, the Dow Jones increased by 0.48%, and the Nasdaq 100 climbed by 1.18%, reflecting growing investor optimism regarding a potential resolution to the Middle East conflict, which has bolstered market confidence.
- Strong Economic Data: The US ADP employment change for March increased by 62,000, surpassing expectations of 40,000, while February retail sales rose by 0.6% month-over-month, indicating robust economic recovery that could influence Federal Reserve policy decisions.
- Interest Rate Expectations: Despite positive economic indicators, hawkish comments from St. Louis Fed President raised concerns about inflation and employment, leading to a mere 1% chance of a 25 basis point rate hike at the upcoming April FOMC meeting, reflecting cautious market sentiment.
- Divergent Stock Performances: Target Hospitality surged over 36% after securing a multi-year contract worth over $550 million, while Nike fell more than 15% due to revenue forecasts indicating a decline, highlighting the market's varied outlook on different companies' futures.
See More
Oric Pharmaceuticals Shares Plunge 28% Amid Safety Concerns
- Significant Stock Drop: Oric Pharmaceuticals' shares plummeted 28% on Wednesday, marking the largest single-day decline in over four years, primarily due to investor concerns regarding the tolerability of its prostate cancer drug at higher doses, although analysts suggest the sell-off may be exaggerated.
- Dose Adjustment: Oric announced a shift to a lower 400 mg dose of its investigational drug Rinzimetostat, which demonstrated a more manageable safety profile compared to the previously tested 600 mg dose, with plans to advance to a global Phase 3 trial in the first half of 2026.
- Analyst Ratings Maintained: Jones Research maintained a ‘Buy’ rating on Oric with a $25 price target, noting that the drug's efficacy appears comparable to Pfizer's competing drug Mevrometostat while potentially offering a better safety profile, indicating continued market confidence in the stock.
- Market Sentiment Shift: Despite the sharp decline in stock price, retail sentiment shifted from ‘neutral’ to ‘extremely bullish’, reflecting optimism about Oric's future potential, with some users expressing that the stock has
See More
US Stocks Rise on Optimism Over Middle East Conflict Resolution
- Market Rally: The S&P 500 Index rose by 0.97%, the Dow Jones Industrial Average by 0.86%, and the Nasdaq 100 by 1.45%, reflecting growing investor confidence amid optimism that the Middle East conflict may soon conclude, which could stabilize global markets.
- Strong Economic Data: The US ADP employment change for March increased by 62,000, surpassing expectations of 40,000, while February retail sales rose by 0.6% month-over-month, indicating robust economic recovery that may influence Federal Reserve policy decisions.
- Interest Rate Outlook: Despite a mere 1% chance of a 25 basis point rate hike at the upcoming FOMC meeting, hawkish comments from St. Louis Fed President raised concerns about inflation and employment risks, potentially affecting investor sentiment and market dynamics.
- Divergent Stock Performances: Target Hospitality surged by over 37% after securing a multi-year contract worth over $550 million, while Nike fell by more than 13% due to revenue forecasts indicating a decline, highlighting varied market reactions to company-specific news.
See More
US Stocks Rise on Optimism Over Middle East Conflict Resolution
- Market Optimism: The S&P 500 index rose by 0.52%, the Dow Jones Industrial Average by 0.43%, and the Nasdaq 100 by 0.68%, reflecting investor optimism regarding a potential resolution to the Middle East conflict, which has fueled a continuation of Tuesday's strong rally.
- Strong Economic Data: The US ADP employment change for March increased by 62,000, surpassing expectations of 40,000, while February retail sales rose by 0.6% month-over-month, exceeding the anticipated 0.5%, bolstering market confidence in economic recovery and potentially influencing future monetary policy.
- Interest Rate Expectations: Despite hawkish comments from the St. Louis Fed President putting pressure on stocks, the market is still pricing in only a 1% chance of a 25 basis point rate hike at the upcoming FOMC meeting on April 28-29, indicating a cautious optimism regarding economic growth.
- Notable Stock Performances: Target Hospitality's stock surged over 28% after securing a multi-year contract worth over $550 million, while nCino's forecast of $569 million to $573 million in subscription revenue for 2027 exceeded market expectations, highlighting strong demand in the tech and service sectors.
See More
Oric Pharmaceuticals Reports New Rinzimetostat Developments
- Clinical Trial Progress: Oric Pharmaceuticals has identified Rinzimetostat (ORIC-944) at a dose of 400 mg once daily as the recommended Phase 3 dose in its Phase Ib study, demonstrating a landmark 5-month radiographic progression-free survival (rPFS) of 84% in post-abiraterone metastatic castration-resistant prostate cancer patients, significantly outperforming standard therapies and indicating strong market competitiveness.
- Safety Profile Advantage: The drug exhibited a notably lower incidence of adverse events in the Phase Ib trial, with nearly all side effects classified as Grade 1 or 2, and far fewer treatment modifications compared to competitor regimens, highlighting its safety and tolerability in clinical applications.
- Future Trial Plans: Oric plans to initiate the Himalayas-1 Phase 3 registrational trial in the first half of 2026, aiming to enroll approximately 600 patients randomized to receive either Rinzimetostat in combination with Darolutamide or a physician's choice of AR inhibitor or chemotherapy, further validating its efficacy.
- Strong Financial Position: As of 2025, Oric reported $392.3 million in cash and cash equivalents, expected to fund its operational plans into the second quarter of 2028, demonstrating financial stability as it advances clinical trials and market expansion.
See More
ORIC Pharmaceuticals Shares Drop After Rinzimetostat Trial Data Release
- Clinical Trial Results: ORIC Pharmaceuticals reported data from its Phase 1b trial of rinzimetostat (ORIC-944) in combination with Bayer's Nubeqa, showing at the recommended dose of 400 mg, patients had radiographic progression-free survival (rPFS) rates of 93%, 84%, and 84% at 3, 4, and 5 months, respectively, indicating a favorable safety profile for long-term use.
- Market Reaction: Despite the positive safety differentiation shown in the trial, ORIC's stock fell approximately 22% in after-hours trading, with analysts like JPMorgan's Anupam Rama suggesting that the market's reaction is an overreaction and does not reflect the potential value of rinzimetostat.
- Future Plans: ORIC intends to initiate a global Phase 3 trial in H1 2026 to evaluate the efficacy of rinzimetostat in combination with darolutamide against the physician's choice of other AR inhibitors or chemotherapy, aiming to further validate its therapeutic benefits.
- Competitive Advantage: The findings align with other PRC2 inhibitors in late-stage development and outperform standard treatments like Pfizer's Xtandi, highlighting ORIC's potential competitive edge in the prostate cancer treatment landscape.
See More
